Saturday 17 October 2026 Export SCNI’s income statement to Excel — free account

Scinai Immunotherapeutics Ltd. Sponsored ADR

Scinai Immunotherapeutics Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 99.2% from fiscal 2024. In the quarter to June 2026, EPS grew 100.4% and free cash flow grew 51.1%, each against the same quarter a year earlier.

0.75 0.15 −16.67%

Follow SCNI

Alert me

Market cap: $640.0K
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: n/a
Altman Z: −16.85
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 0.64

Revenue —

Net Income (1.00)

Free Cash Flow (6.62)

Net Debt (2.57)

Current Ratio 1.56

Debt/Equity 0.02

P/E ratio 0.01

Fwd P/E 0.00

P/S ratio 0.00

P/B ratio 0.05

Past 5Y EPS Growth —

This Y EPS Growth (15.58%)

Next Y EPS Growth —

Next Y revenue growth (100.00%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 0.06%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	5	2	2	3
Receivables	0	0	0	1
Inventory	—	—	—	—
Other	—	—	—	—
	5	2	2	3

	2023	2024	2025	Q'26
Payables	1	0	0	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	2	2	2	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(0.59%)	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	—	—	—	—
’25	1	—	—	—	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(2)	—	—	—
’25	(1)	(2)	—	—	(6)
’24	(1)	(2)	(5)	—	(6)
’23	(3)	(3)	(8)	(1)	(9)
’22	(1)	—	(7)	(1)	(7)
’21	(1)	(2)	(2)	(7)	(7)
’20	—	(13)	(3)	(6)	(23)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(3)	—	—	—
’25	(1)	(2)	—	—	(6)
’24	(1)	(2)	(5)	—	(6)
’23	(3)	(3)	(9)	(1)	(10)
’22	(2)	—	(7)	(1)	(8)
’21	(1)	(2)	(2)	(8)	(8)
’20	—	(14)	(4)	(6)	(24)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	9.40	—	—	—	—
’25	(8.07)	—	—	—	(35.60)
’24	(40.00)	—	123.93	—	59.50
’23	(120.00)	(111.00)	66.22	(2.40k)	(166.37)
’22	(132.92)	(159.77)	244.52	(259.31)	(307.48)
’21	(190.00)	(2.73k)	(200.00)	2.53k	(581.57)
’20	(80.00)	(1.12k)	1.20k	(360.00)	(120.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	3,040.00	3,582.00	3,510.00	4,430.00	2,350.00	1,360.00	283.00	50.10	22.30	6.13	Analyst estimates 2026–2028 Powerpack
	High	4,100.00	10,750.00	7,713.00	9,390.00	62,000.00	7,220.00	2,400.00	360.00	89.20	61.80
People
People	Employees	14	14	21	25	21	15	33	31	31	45
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.03
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	1	1
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	(88.15)	(202.29)
	EBT	(2)	(10)	(23)	(32)	(1)	(8)	(6)	(6)	5	(8)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	728.88	(633.64)
	Net income	(2)	(10)	(23)	(32)	(1)	(8)	(6)	(6)	5	(8)
	Depreciation	0	0	0	0	1	0	1	1	2	1
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.16	5.61
	Earnings	(800.00)	(1,980.00)	(3,600.00)	(3,600.00)	(120.00)	(581.57)	(307.48)	(166.37)	59.50	(35.60)
	Cash flow	(738.53)	(579.80)	(2,347.85)	(2,719.15)	(2,032.61)	(526.67)	(384.39)	(239.95)	(78.60)	(25.83)
	Capex	(1.47)	(260.00)	(968.46)	(262.20)	(167.30)	(9.86)	(44.23)	(16.29)	(0.15)	(0.10)
	Free cash flow	(740.00)	(839.80)	(3,316.31)	(2,981.34)	(2,199.91)	(536.52)	(428.62)	(256.24)	(78.75)	(25.93)
	Book value	1,959.41	3,245.00	(1,281.23)	(2,295.49)	(409.01)	69.65	(93.12)	(116.85)	123.78	34.70
	Shares, m	0	0	0	0	0	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	0.00	0.00
	P/S	—	—	—	—	—	—	—	—	0.00	0.00
	P/B	—	—	—	—	—	—	—	—	0.65	0.56
	EV/Sales	—	—	—	—	—	—	—	—	0.00	0.00
	EV/FCF	—	—	—	—	—	—	—	—	(0.22)	(0.01)
Cash, $m
Cash, $m	Operating cash flow	(3)	(3)	(15)	(22)	(23)	(7)	(7)	(9)	(6)	(6)
	Capex	0	(1)	(6)	(2)	(2)	0	(1)	(1)	0	0
	Free cash flow	(3)	(4)	(22)	(24)	(24)	(8)	(8)	(10)	(6)	(6)
Balance, $m
Balance, $m	Working capital	6	20	15	16	(17)	15	12	4	1	0
	Total debt	—	—	25	36	21	27	20	19	0	0
	Net debt	(7)	(21)	5	15	18	10	6	14	(2)	(2)
	Shareholders’ equity	7	16	(8)	(19)	(5)	1	(2)	(5)	10	8
Returns, %
Returns, %	ROA	(25.94)	(63.49)	(90.37)	(102.37)	(5.41)	(33.00)	(19.61)	(29.19)	31.02	(66.26)
	ROIC	(2,545.23)	0.00	0.00	0.00	10.79	(63.87)	(168.33)	(61.97)	(66.31)	(71.57)
	ROE	(31.31)	(87.09)	(592.81)	232.74	11.86	461.27	1,489.97	205.40	(4,379.91)	(243.39)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CRIS Curis, Inc.	$1.1M	— (loss-making)	— (loss-making)	−65.98% (below 0%: shrinking)	n/m	−20.44% (below 0%: shrinking)	100.00%	0.00%	Compare
MNTRQ 9 Meters Biopharma, Inc.	$1.0M	— (loss-making)	—	−25.99% (below 0%: shrinking)	n/m	+0.01% (above 0%: growing)	0.00%	0.00%	Compare
ZVSA ZyVersa Therapeutics, Inc.	$970.0K	— (loss-making)	—	—	n/m	+54.91% (above 0%: growing)	0.00%	0.00%	Compare
LYRA Lyra Therapeutics, Inc.	$870.0K	— (loss-making)	— (loss-making)	−96.65% (below 0%: shrinking)	n/m	+45.44% (above 0%: growing)	100.00%	(101,685.71%)	Compare
BTTX Better Therapeutics, Inc.	$850.0K	— (loss-making)	—	—	n/m	+20.43% (above 0%: growing)	0.00%	0.00%	Compare
SEELQ Seelos Therapeutics, Inc.	$700.0K	— (loss-making)	— (loss-making)	+11.90% (above 0%: growing)	n/m	+83.54% (above 0%: growing)	100.00%	(834.84%)	Compare
ATXI Avenue Therapeutics, Inc.	$680.0K	— (loss-making)	— (loss-making)	—	n/m	−169.89% (below 0%: shrinking)	100.00%	0.00%	Compare
SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR	$640.0K	0.0×	— (loss-making)	—	n/m	+51.13% (above 0%: growing)	(228.63%)	(504.50%)
BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR	$440.0K	— (loss-making)	—	−32.27% (below 0%: shrinking)	+96.36% (above 0%: growing)	−0.17% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$860.0K	—	—	−32.27%	—	+10.22%	50.00%	0.00%

All 614 Biotechnology stocks →

Scinai Immunotherapeutics Ltd. Sponsored ADR (SCNI) key facts

Strength: Scinai Immunotherapeutics Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 99.2% from fiscal 2024.
Scinai Immunotherapeutics Ltd. Sponsored ADR (SCNI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SCNI traded at $0.75, a market capitalization of $640,000.00.
Return on equity was −243.4% and debt-to-equity 0.02.
Its Altman Z-score is −16.85 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.